InnoSIGN

InnoSIGN is a biotechnology start-up revolutionizing precision medicine with its OncoSIGNal pathway activity profiling technology. Founded in 2020, the company has its headquarters at the High Tech Campus in Eindhoven (NL) and in Mason, Ohio (US). In March 2022, InnoSIGN secured a significant €7.33M Series A investment backed by prominent investors including Casdin Capital, Life Science Angels, Thuja Capital, and Brabant Development. InnoSIGN's innovative product, OncoSIGNal, plays a crucial role in advancing next-generation precision medicine by translating molecular data into functional cell behavior, thus contributing to a better understanding of disease mechanisms in oncology. The company is passionate about improving personalized treatment for cancer patients, showcasing its commitment to making a positive impact in the field of oncology.